Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
66 hedge funds and large institutions have $347M invested in Mirati Therapeutics, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 13 reducing their positions, and 9 closing their positions.
146% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 13
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
14% more funds holding
Funds holding: 58 → 66 (+8)
8% more capital invested
Capital invested by funds: $319M → $347M (+$27.1M)
1% more call options, than puts
Call options by funds: $809K | Put options by funds: $799K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$20M |
| 2 |
DM
Deerfield Management
New York
|
+$10.7M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$4.79M |
| 4 |
BC
Broadfin Capital
New York
|
+$1.57M |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$17.3M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$11.4M |
| 3 |
AG
Artal Group
Luxembourg
|
-$5.56M |
| 4 |
QF
QVT Financial
New York
|
-$4.83M |
| 5 |
First Eagle Investment Management
New York
|
-$1.68M |
MRTX Hedge Fund Activity: Q2 2015 in Review
66 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q2 2015, worth a combined $347M — up 8.5% from $319M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new MRTX positions and 9 closed out — a net gain of 8 holders — while 32 added to existing stakes and 13 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $20M. The largest seller was OrbiMed, cutting an estimated $17.3M.
- 66 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q2 2015, up from 58 in Q1 2015.
- Funds reported $347M of Mirati Therapeutics, Inc. Common Stock stock for Q2 2015, up 8.5% quarter-over-quarter.
- 17 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q2 2015 and 9 closed out, a net change of +8 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q2 2015 was Avoro Capital Advisors, an estimated $20M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q2 2015 was OrbiMed, an estimated $17.3M sold.
Based on aggregated 13F filings for Q2 2015.